Here's a surprising fact: the flu shot you get might not be giving you the best protection, especially if you're over 65. But here's where it gets controversial—a recent study suggests that a high-dose flu vaccine could be a game-changer for seniors, whether they have diabetes or not. And this is the part most people miss: it’s not just about preventing the flu; it’s about reducing serious health complications like heart and lung issues.
TOPLINE:
A groundbreaking study reveals that among adults aged 65 and older, the high-dose inactivated influenza vaccine (HD-IIV) outperformed the standard-dose version (SD-IIV) in preventing hospitalizations related to cardiorespiratory, cardiovascular, and influenza-related illnesses. The surprising twist? These benefits held true regardless of whether the individuals had diabetes.
METHODOLOGY:
This study, a secondary analysis of the DANFLU-2 trial, spanned the 2022/2023 to 2024/2025 flu seasons. It aimed to compare the effectiveness of HD-IIV and SD-IIV in older adults, focusing on severe respiratory and cardiovascular outcomes. Here’s how it worked: over 332,000 seniors (average age 73.7, 48.6% women) were randomly given either the high-dose vaccine (60 μg of antigen per strain) or the standard-dose (15 μg per strain). Among them, 43,881 had diabetes, identified through medical records or A1c levels. The study tracked participants from 14 days after vaccination until May 31 of the following year, monitoring hospitalizations for cardiorespiratory diseases, cardiovascular diseases, influenza, and lab-confirmed flu cases.
TAKEAWAY:
The results were eye-opening. The high-dose vaccine significantly reduced hospitalizations for all tracked conditions compared to the standard dose. Interestingly, the benefits were consistent whether participants had diabetes or not. However, here’s a bold point to consider: among those with diabetes, individuals who had lived with the condition for over 5 years saw even greater benefits from the high-dose vaccine in avoiding cardiorespiratory hospitalizations. This raises the question: should diabetes duration influence vaccine recommendations?
IN PRACTICE:
The study’s authors emphasize that while these findings are exploratory, they highlight the importance of flu vaccination and suggest that the high-dose vaccine could be particularly beneficial for those with diabetes. This could spark a shift in how we approach flu prevention for seniors.
SOURCE:
Led by Dr. Anne Bjerg Nielsen of Copenhagen University Hospital, this study was published in JAMA Internal Medicine on January 12, 2026. It’s a timely reminder of the evolving science behind vaccines and their broader health impacts.
LIMITATIONS:
It’s important to note that the DANFLU-2 trial wasn’t designed for subgroup analyses, so these findings are exploratory. Additionally, the primary outcome of hospitalization for influenza or pneumonia was neutral, and diabetes duration might have been underestimated due to data limitations.
DISCLOSURES:
The study was funded by Sanofi, and several authors have financial ties to the company, including employment, shares, and personal fees. This raises the question: could industry funding influence the interpretation of results? We’ll leave that for you to decide.
Final Thought:
As we age, our immune systems need all the help they can get. This study challenges us to rethink how we protect seniors from the flu and its complications. But here’s the big question: should high-dose vaccines become the standard for older adults, especially those with diabetes? Let us know your thoughts in the comments—we’d love to hear your perspective!
